Edoxaban in cancer associated isolated distal DVT
Erman Akkus, Medical Oncology Fellow at Ankara University, shared a recent article by Yugo Yamashita on X:
“Edoxaban for 12 vs 3 months in cancer associated isolated distal DVT Oncology DVT Study at Circulation.
Symptomatic recurrent VTE or VTE-related death 1% vs 7.2% (OR: 0.13; 95% CI, 0.03–0.44) Bleeding 9.5% vs 7.2%, (OR: 1.34; 95% CI, 0.75–2.41) Cancer and treatment types (platin, beva etc) are not specified 12 vs 6 months?”
Authors: Yugo Yamashita, Takeshi Morimoto, Nao Muraoka, Takuya Oyakawa, Michihisa Umetsu, Daijirou Akamatsu, Yuji Nishimoto, Yukihito Sato, Takuma Takada, Kentaro Jujo, Yuichiro Minami, Yoshito Ogihara, Kaoru Dohi, Masashi Fujita, Tatsuya Nishikawa, Nobutaka Ikeda, Go Hashimoto, Kazunori Otsui, Kenta Mori, Daisuke Sueta, Yukari Tsubata, Masaaki Shoji, Ayumi Shikama, Yutaka Hosoi, Yasuhiro Tanabe, Ryuki Chatani, Kengo Tsukahara, Naohiko Nakanishi, Kitae Kim, Satoshi Ikeda, Makoto Mo, Yusuke Yoshikawa and Takeshi Kimura.
Erman Akkus is a medical oncology fellow at the Ankara University, Faculty of Medicine. Previously, he was an Internal Medicine Resident at the Ankara University, Faculty of Medicine. He was also a Visiting Researcher at the University of Oslo. He completed his education from the Medical University of Vienna.
More posts featuring Erman Akkus.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023